A Study of Enfortumab Vedotin Plus Pembrolizumab and/or Chemotherapy for Patients With Urothelial Bladder Cancer (EV-103)
Carcinoma, Transitional Cell Urinary Bladder Neoplasms Urologic Neoplasms Renal Pelvis Neoplasms Urothelial Cancer Ureteral Neoplasms Urethral Neoplasms ASG-22ME ASG-22CE Antibody-drug conjugate Antineoplastic agents CPI Enfortumab vedotin Locally advanced urothelial cancer Cisplatin Drug therapy Carboplatin Metastatic urothelial cancer Nectin-4 Gemcitabine Checkpoint Inhibitors Pembrolizumab Neoplasms Pelvic Neoplasms Dose Escalation: Enfortumab Vedotin + Pembrolizumab
Lead Scientist at UCSF
- Terence Friedlander
I am a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. My research is focused on understanding the basic biology these malignancies and in developing novel therapeutic ways to treat disease.
- accepting new patients
- Start Date
- Completion Date
- Astellas Pharma Global Development, Inc.
- Phase 1
- Study Type
- Last Updated